137 results on '"Tomsic, Matija"'
Search Results
2. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
3. Molecular maps of synovial cells in inflammatory arthritis using an optimized synovial tissue dissociation protocol
4. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
5. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
6. Janus kinase inhibitors and their use in non-infectious orbital inflammatory disorders: new treatment possibilities? A case series.
7. Synergy between 15-lipoxygenase and secreted PLA₂ promotes inflammation by formation of TLR4 agonists from extracellular vesicles
8. Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts
9. Solvation of nonionic poly(ethylene oxide) surfactant Brij 35 in organic and aqueous-organic solvents
10. Human mesenchymal stromal cells from different tissues exhibit unique responses to different inflammatory stimuli
11. Colorimetric cutoff indication of relative humidity based on selectively functionalized mesoporous silica
12. Structural, rheological and dynamic aspects of hydrogen-bonding molecular liquids: Aqueous solutions of hydrotropic tert-butyl alcohol
13. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
14. Supramolecular structure vs. rheological properties: 1,4–Butanediol at room and elevated temperatures
15. Supra-molecular structure and rheological aspects of liquid terminal 1,n‑diols from ethylene glycol, 1,3‑propandiol, 1,4‑butanediol to 1,5‑pentanediol
16. Characterization of the supramolecular assembly in 1,4-butanediol
17. Supramolecular structure of methyl cellulose and lambda- and kappa-carrageenan in water: SAXS study using the string-of-beads model
18. Performance of various models in structural characterization of n-butanol: Molecular dynamics and X-ray scattering studies
19. Dynamics of liquid-crystalline emulsion droplets arrested in hydrogels: Addressing the multiple scattering problem in turbid systems
20. Electroporation of archaeal lipid membranes using MD simulations
21. Amorphous supramolecular structure of carboxymethyl cellulose in aqueous solution at different pH values as determined by rheology, small angle X-ray and light scattering
22. Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]
23. Metabolic fingerprints of human primary endothelial and fibroblast cells
24. Serum amyloid A activation of human coronary artery endothelial cells exhibits a neutrophil promoting molecular profile
25. Structural investigation of carboxymethyl cellulose biodeterioration by Bacillus subtilis subsp. subtilis NCIB 3610
26. The impact of the COVID-19 pandemic on the global assessments of rheumatology clinimetrics: Data from a mobile application. A comment on article by Nagy E, et al.: “The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned”
27. Immune mediated events timely associated with COVID-19 vaccine. A comment on article by Badier, et al.: “IgA vasculitis in adult patients following vaccination by ChadOx1 nCoV-19”
28. Defining disease activity states and clinically meaningful improvement in primary Sjögrenʼs syndrome with EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
29. Validation of EULAR primary Sjögrenʼs syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
30. Internally self-assembled particles entrapped in thermoreversible hydrogels
31. The curiously suspicious: Infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients
32. A thermoreversible double gel: Characterization of a methylcellulose and κ-carrageenan mixed system in water by SAXS, DSC and rheology
33. Validation of the classification criteria for cryoglobulinaemic vasculitis
34. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to countryʼs wealth?
35. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
36. DRUG RETENTION RATES AND TREATMENT OUTCOMES IN 1860 AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK
37. Structural properties of pure simple alcohols from ethanol, propanol, butanol, pentanol, to hexanol: Comparing Monte Carlo simulations with experimental SAXS data
38. Inequities in access to biologic and synthetic DMARDs across 46 European countries
39. Endothelial function is impaired in patients with primary antiphospholipid syndrome
40. Ternary systems of nonionic surfactant Brij 35, water and various simple alcohols: Structural investigations by small-angle X-ray scattering and dynamic light scattering
41. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
42. Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
43. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
44. EULAR Sjögrenʼs Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögrenʼs syndrome
45. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
46. Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? - Results from the EuroSpA Research Collaboration
47. Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care - Was PRO Remission Achieved? Results from the EuroSpA Collaboration
48. 6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
49. POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION
50. TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAIVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT - ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.